Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

Drugs like Ozempic and Mounjaro are GLP-1-based medications, meaning they mimic gut hormones that help regulate appetite and ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Gyms overflowing, menus full of small plates and a surge in 'Ozempic face' supplements are just a few ways in which ...